SWOG clinical trial number
CTSU/E2204

An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma

Closed
Phase
II
Abbreviated Title
PANCREAS
Activated
10/15/2006
Closed
01/09/2008
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Gemcitabine hydrochloride Radiation Therapy Bevacizumab Capecitabine Cetuximab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information.

Publication Information Expand/Collapse

2010

ECOG 2204: An intergroup phase II study of cetuxamab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC)

J Berlin;PJ Catalano;Y Feng;AM Lowy;AW Blackstock;PA Philip;RR McWilliams;J Abbruzzese;AB Benson Journal of Clinical Oncology 28:7s (suppl; abstr 4024) poster

Other Clinical Trials

SWOG Clinical Trial Number
S9304A-ICSC

Investigation of Thioredoxin-1 Family Protein Expression in Rectal Cancer

Research Committee(s)
Gastrointestinal Cancer
Closed
SWOG Clinical Trial Number
SWOG-8037

Combined Therapies for Squamous Cell Carcinoma of the Esophagus

Research Committee(s)
Gastrointestinal Cancer
Activated
02/16/1981
Closed
01/19/1984
Closed
Phase
II
Published
SWOG Clinical Trial Number
SWOG-8591(NCI Intergroup #0035)

An Evaluation of Levamisole Alone or Levamisole plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon

Research Committee(s)
Gastrointestinal Cancer
Activated
01/14/1985
Closed
10/01/1987
Closed
Phase
Published